Dr. Stasiu Nowak is a member in the firm’s life sciences practice group, focusing his practice on drafting and prosecuting patent applications and performing patent landscape analyses relating to molecular biology and immunology, including cancer treatment, platform cell biology technologies, DNA sequencing technologies, vaccines, and antibody-based therapeutics. Stasiu works with a variety of clients, ranging from small biotechnology companies to universities and non-profit research foundations with large and complex patent estates.
Stasiu's area of particular technical expertise is in the area of cell and molecular biology, immunology, and infectious disease treatment. Representative client technologies include: cancer biology and treatment, enhanced adjuvant technologies, conjugate immunogens for therapeutic vaccines, antigen-specific T cell manipulation, antigen tolerance technologies, RNA interference based therapies, disease diagnostics, platform reagents for antigen detection, and platform technologies for gene expression induction and analysis. Other representative client technologies have involved plant patents, food processing systems, water treatment systems for infectious agents, metabolic engineering for enhanced biofuel production, and cellulose fiber technologies for pulp and paper production.
Prior to joining COJK, Stasiu conducted research in identifying genetic determinants of successful host immune defense responses and parasite resistance phenotypes. His doctoral research experience includes gene expression profiling of host and parasites during the course of infection, and gene expression knockdown techniques using RNAi to address the roles of candidate genes. Prior to his graduate studies, Stasiu was also involved in the discovery and identification of ligands for orphan G-protein coupled receptors (GPCRs).
Stasiu was selected to Best Lawyers' inaugural list of “Ones to Watch” in 2020, for outstanding professional excellence in private practice in the United States.